By Michael J. Dattoli, MD
with Virginia Carnahan, CPRC

When prostate cancer spreads beyond its original site and is no longer locally confined to the prostate gland – a process called metastasis–it marks a significant turning point in the disease. For many, this diagnosis can feel overwhelming, as metastatic cancer has historically been considered incurable. However, the landscape of advanced prostate cancer treatment has evolved significantly over the past two decades thanks to technological progress and our growing
knowledge of the disease process. Today, there are innovative strategies that offer patients hope for improved survival while maintaining their quality of life.

Understanding Metastatic Prostate Cancer

Metastatic prostate cancer occurs when cancer cells spread from the prostate to other parts of the body, most commonly the lymph nodes, bones, lungs, and liver. Historically, metastatic prostate cancer was treated with systemic therapies alone – such as androgen deprivation therapy (ADT) and chemotherapy – aimed at controlling cancer throughout the body. However, these approaches often left persistent cancer cells in the prostate gland itself or in localized metastatic sites, and these persistent cancer cells often become resistant to systemic agents.

As a result, these remaining cancer cells often progress and spread, leading to problems within the prostate region itself, and are also left to colonize distant sites such as the lymph nodes, bone, lungs and liver.

A Shift in Perspective

For decades, the prevailing belief was that treating the primary tumor in cases of metastasis was futile. However, emerging evidence has challenged this view. Research now suggests that treating the prostate gland – even in the setting of metastasis – can influence outcomes by reducing tumor burden and potentially slowing or preventing further spread.

One of the most intriguing concepts in this field is that of the abscopal effect. This phenomenon describes how local treatments like radiation therapy not only target tumors at their primary site of origin but also stimulate systemic immune responses that shrink untreated tumors elsewhere in the body. This discovery has opened new doors for integrating local and systemic therapies.

1. The STAMPEDE Trial (2016)

This large, randomized trial demonstrated that adding radiation therapy to systemic treatments (such as ADT) provided a significant survival benefit for men with metastatic prostate cancer, and especially for those having low-volume metastatic disease. The study showed that targeting the primary tumor with radiation improved outcomes even when metastases were present.

2. The HORRAD Trial

This clinical trial explored the benefits of combining radiation therapy with ADT specifically for men with bone metastases. The results demonstrated beneficial outcomes in patients having low-volume skeletal metastases, although even treating high-volume disease with this combined approach was associated with several superior clinical and radiographic endpoints.

3. Oligometastatic Disease Concept

A concept introduced in 1995 by University of Chicago researchers Weichselbaum and Hellman, who coined the term “oligometastases,” referring to cases where cancer has spread to a limited number of distant sites (typically up to Thve) outside the prostate. Studies suggest that patients with oligometastatic disease may achieve long-term complete remissions – or even cure – through aggressive local treatments targeting both the primary tumor and metastatic sites.

Modern Treatment Strategies: A Multi-Pronged Approach

The treatment of advanced prostate cancer now often involves a combination of therapies tailored to each patient’s disease characteristics.

Below are key components of this multi-pronged approach:

1. Treating the Primary Tumor

Radiation therapy directed at the prostate gland remains a cornerstone of definitive treatment for localized prostate cancer. By reducing the tumor burden at its source, this approach delays progression and halts and minimizes complications such as urinary obstruction or pelvic pain. But recent clinical trials have validated the use of local radiation to the prostate even in the metastatic setting.

2. Metastasis-Directed Therapy (MDT)

Advances in imaging technologies like PSMA PET scans makes it possible to precisely identify metastatic sites early in their development.

This has enabled targeted radiation to treat these sites directly – a strategy known as metastasis-directed therapy (MDT).

• MDT can be particularly effective for patients with oligometastatic disease.
• Precision radiation techniques such as Intensity Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiotherapy (SBRT) are used to deliver highly focused doses to metastatic lesions while sparing surrounding healthy tissue.

3. Systemic Therapies

Systemic treatments remain essential for controlling widespread disease.

They include the following:

• Androgen Deprivation Therapy (ADT): In its multivarious forms, ADT represents the historic foundation of systemic therapy for prostate cancer.
• Androgen Receptor Pathway Inhibitors: Drugs like enzalutamide (Xtandi), apalutamide (Erleada), abiraterone (Zytiga), and darolutamide (Nubeqa®) enhance ADT by blocking testosterone signaling more effectively than ADT alone.
• Chemotherapy: Docetaxel or cabazitaxel are often used in combination with hormone therapy.
• Radioligand Therapy: Agents like Xo Thgo (radium-223) and Pluvicto (lutetium-177) deliver targeted radiation directly to cancer cells, body-wide.
• Immunotherapy: Sipuleucel-T (Provenge) is an FDA-approved vaccine-based immunotherapy for advanced prostate cancer, often referred to “designer immunotherapy.”
• Molecularly Targeted Therapies: Genomic pro”ling can identify actionable mutations for personalized treatments using PARP inhibitors or monoclonal antibodies.
• Precision Medicine: Using state-of-the-art imaging technologies.
  • PSMA PET Imaging provides unparalleled accuracy in identifying even small metastases.
  • Combidex/USPIO Nanoparticle Imaging is used to detect the earliest microscopic lymph node involvement.

These tools allow clinicians to stratify patients into low-volume versus high-volume metastatic disease categories and tailor treatment plans accordingly.

Real-World Success Stories

At the Dattoli Cancer Center, these advanced concepts have been applied with remarkable success. Over the past two decades, many patients with advanced metastatic prostate cancer have achieved longterm complete remissions – many remaining cancer-free for well over 10 years – through aggressive yet precise protocols that are safe.

Key elements of our approach include:

• Dynamic Adaptive Radiation Therapy (DART), which is an extremely precise form of external beam radiation used to target both the prostate and regional lymph nodes.
• Metastasis-directed DART for skeletal or visceral metastases.
• Integration of systemic therapies such as ADT and androgen receptor inhibitors.
• Use of radioligand therapies (e.g., Xo”go, Pluvicto) and immunotherapies (e.g., Provenge).
• Molecular pro”ling to guide precision medicine strategies. Toxicity pro”les have been very mild, making these treatments both effective and well-tolerated by our patients, especially compared to chemotherapy.

The Path Forward

The treatment paradigm for metastatic prostate cancer has shifted dramatically from one of palliative care alone to one that embraces long-term curative potential.

A comprehensive strategy combining local therapies, metastasisdirected interventions, and systemic agents offers new hope for extending survival and improving quality of life.

For patients diagnosed with metastatic prostate cancer today – including both newly diagnosed patients and those who experience recurrence after initial treatment – there is no longer a single path forward but rather a spectrum of options tailored to individual needs and disease characteristics. By leveraging advances in imaging, precision medicine, and multidisciplinary care, we are entering an era where even advanced stages of this disease can be managed with much optimism about potential success in the near-term.

With this article, my team and I hope to inspire both physicians and patients alike by highlighting how far we’ve come – and how much further we can go – in transforming outcomes for men living with metastatic prostate cancer.
Download PDF